Kirkeby, Katrine
Novo Nordisk (Denmark)
2 papers on CoChatORCID 0000-0001-6065-1583
Most cited papers
- Verified
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Gasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 46
- Verified
Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
Gabe, M. B. N., Breitschaft, A., Knop, F. K., Hansen, M. R., Kirkeby, K., Rathor, N., & Adrian, C. L. (2024) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity
Cited by 46
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free